Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 26, 2018
ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multidrug ...
June 26, 2018
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
TEL AVIV, Israel, June 26, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments ...
June 25, 2018
BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy
NEW YORK and PETACH TIKVAH, Israel, June 25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
June 25, 2018
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today ...
June 25, 2018
Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer
DUBLIN, Ireland, June 25, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies ...
June 25, 2018
Genkyotex Expands License Agreement for Vaxiclase Platform with Serum Institute of India
ARCHAMPS, France--(BUSINESS WIRE)--Regulatory News: Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces that ...
June 25, 2018
Kiadis Pharma to present at HollandBIO's Dutch Biotech Event 2018
Amsterdam, The Netherlands, June 25, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company ...
June 25, 2018
ArQule Added to the Russell 2000® Index
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (ARQL) today announced that it has been added to the Russell 2000® Index, a subset of the Russell 3000® Index, effective as ...
June 25, 2018
BioTime Licenses GMP Cell Line to Goliver Therapeutics
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
June 25, 2018
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes
RAMSEY, N.J. and BOCA RATON, Fla., June 25, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets ...
June 25, 2018
PolarityTE Added to Russell 3000® and Russell 2000® Indexes
SALT LAKE CITY, June 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of ...
June 25, 2018
Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
June 25, 2018
Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (FBIO) Company developing treatments for rare and life-threatening diseases, today ...
June 25, 2018
Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that additional data for Afrezza from the STAT study (STudy comparing prandial ...
June 25, 2018
Tyme Technologies, Inc. Set to Join Russell 3000® Index
NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set ...
June 25, 2018
CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes
NEWARK, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
June 25, 2018
Catalyst Biosciences Joins the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology ...
June 25, 2018
Albireo Added to Russell 2000® Index
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
June 25, 2018
MannKind Set to Join Russell 3000® Index
WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for ...
June 22, 2018
UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy
Pratteln, Switzerland, June 22, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the UK`s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed the Early Access to ...
Page 51 of 138